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The increasing incidence of respiratory diseases such as 
cystic fibrosis, asthma, chronic obstructive pulmonary 
disease, infectious diseases, lung cancer and tuberculosis, 
makes pulmonary drug delivery a main point of focus in 
current drug delivery research. Dry powder inhalers (DPIs) 
have been the subject of widespread research interest over 
the past few years. However, obtaining high drug 
aerosolization efficiency is a major challenge for DPI 
formulations because most DPIs still have relatively poor 
drug aerosolization performance (1). Despite the extensive 
research on lactose as a carrier in DPI formulations (2–4), 
lactose still suffers from some serious pitfalls including 
unsuitability for diabetic patients, interaction with certain 
drugs containing amino groups, for example, formotrol and 
budesonide, and interaction with peptides and protein drugs 
due to its reducing function (5). Therefore the objective of 
this study was to introduce freeze-dried mannitol as an 
alternative promising carrier in DPI formulations containing 
salbutamol sulphate (SS) as a model drug. This study was 
performed with a view to propose optimal mannitol product 
(freeze-dried mannitol versus spray-dried mannitol and 
commercial mannitol) for SS based drug–carrier dry 
powder inhaler formulations. 
 
MATERIALS AND METHODOLOGY 
Commercial mannitol (CM) and spray dried mannitol 
(SDP) and micronized salbutamol sulphate (LB Bohle, 
Germany) were purchased. Mannitol was freeze dried using 
a SCANVAC CoolSafe™ freeze-dryer. Different mannitol 
powders were sieved to collect 63-90 µm particles and then 
characterized in terms of size (laser diffraction), shape 
(scanning electron microscopy, SEM), surface morphology 
(Atomic force microscopy (AFM)), solid state (differential 
scanning calorimetry (DSC), fourier transform infrared 
spectroscopy (FT-IR) and powder X-ray diffraction 
(PXRD)), density (ultrapycnometer 1000) and flowability. 
SS-mannitol aerosol formulations were evaluated in terms 
of drug homogeneity, SS-mannitol adhesion and in vitro 
aerosolization performance of SS using a multistage liquid 
impinge and Aerolizer
®
 inhaler device at 92 L/min flow 
rate.  
RESULTS AND DISCUSSION  
SEM images of all monnitol used and their aerosolozation 
pattern through MSLI were shown in Figure 1. Figure 1 
shows that  Freeze dried mannitol demonstrated had 
superior DPI performance with a fine particle fraction 
believed  to be the highest so far reported in literature for 
salbutamol sulphate (SS) under similar protocols (FPF=46.9 
%) (Figure 1). To a lesser extent, spray dried mannitol 
produced better aerosolization performance than 
commercial mannitol. Freeze dried mannitol demonstrated 
elongated morphology and poor flowability, whereas spray 
dried mannitol demonstrated spherical morphology and 
excellent flowability. Commercial mannitol demonstrated 
angular morphology and good flowability (Figure 1). 
 
 
Figure 1. SEM images various mannitol samples (top figure) 
and the amounts of SS deposited on inhaler plus mouthpiece 
adaptor (I&M), induction port (IP) and different multi stage 
liquid impinger stages. 
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Solid state analyses (Figures not shown) demonstrated that 
CM was β-mannitol whereas SDM was mixtures of α- and 
β-mannitol and FDM sample crystallized as a mixture of α-, 
β-, and δ-mannitol forms. Such results indicate the 
suitability of the applied freeze drying method to prepare 
crystalline mannitol product. α-, β-, and δ- mannitol 
polymorphic forms are stable for minimum 5 years in dry 
atmosphere at 25 °C. 
Roughness analysis (5 × 5 µm) confirmed that CM particles 
(Rq = 300.1±37.9 nm, Ra = 220.0±17.4 nm) have relatively 
rougher surfaces than SDM particles (Rq = 189.5±17.6 nm, 
Ra = 157.2±13.9 nm) which in turn demonstrated 
quantitatively rougher surface than FDM particles (Rq = 
14.2±10.3 nm, Ra = 8.7±1.9 nm) (Figure 1). Freeze dried 
mannitol did not show smaller geometric size than spray 
dried mannitol, however, demonstrated the highest powder 
porosity. 
CM showed similar true density (particle density) to the 
value reported in literature for β-D-mannitol (1.52 g/cm3). 
However, SDM and FDM particles showed different true 
densities compared to CM (1.45 and 1.47 g/cm
3
 
respectively) which could be ascribed to their different 
molecular configuration induced by their different 
polymorphic form and different size. 
Freeze dried mannitol generated the weakest SS–mannitol 
adhesive forces whereas commercial mannitol generated the 
highest SS–mannitol adhesive forces. It was clear that the 
smoother the mannitol surface the weaker the SS–mannitol 
adhesive forces. 
Among mannitol powders, SDM showed the best flow 
properties (excellent flow character, CI = 14.0±0.8 %) 
whereas FDM showed the poorest flow properties (poor 
flow character, CI = 27.2±1.2 %). It is believed that 
spherical shape of SDM powder particles renders the SDM 
powder better flowability. Poorer flowability for FDM 
powder could be ascribed to its more irregular particle 
shape (Figures 1) which induces pronounced internal 
friction (geometric interlocking) within FDM powder. 
No apparent relationship was obtained between fine particle 
fraction and mannitol size, shape, or flowability descriptors. 
However, mannitol products with higher powder porosity 
and weaker SS–mannitol adhesive forces produced higher a 
fine particle fraction of SS (Figure 2). 
It was suggested that the porosity of carrier powder is an 
important physical property that can be considered as a key 
optimization parameter, which might be predictive of in 
vitro aerosolization performance of dry powder inhaler 
formulations. 
Among angular, spherical and elongated shaped mannitol 
particles, formulators can anticipate better drug delivery to 
the lung in case of elongated shape mannitol (Figure 1).  
 
  
Figure 2. FPF of SS in relation to T50% (the time at which 50% 
of particles detach from carrier particles due to sieving) and 
porosity of mannitol powder. 
CONCLUSIONS 
The use of freeze drying technique can constitute an 
important step used in the pharmaceutical industry towards 
preparing freeze dried carrier particles which could help to 
solve some problems connected to drug-carrier dry powder 
aerosol formulations. 
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